All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Entresto's label expansion is based on efficacy and safety evidence observed in PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with guideline-defined HFpEF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inclisiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Leqvio
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Approval is based on the results of the robust ORION clinical development program, where Leqvio provided an effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction of up to 52% in patients with elevated LDL-C, despite maximally tolerated statin therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): lomitapide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lojuxta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2020
Details:
Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sacubitril valsartan sodium hydrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd
Deal Size: Undisclosed Upfront Cash: $90.0 million
Deal Type: Agreement March 02, 2020
Details:
Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.